Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

1,752JPY
21 Nov 2014
Price Change (% chg)

¥12 (+0.66%)
Prev Close
¥1,741
Open
¥1,740
Day's High
¥1,758
Day's Low
¥1,734
Volume
3,364,300
Avg. Vol
3,200,466
52-wk High
¥2,007
52-wk Low
¥1,570

4568.T

Chart for 4568.T

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company has two business segments. The Daiichi Sankyo Group segment is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and... (more)

Overall

Beta: 0.67
Market Cap (Mil.): ¥1,234,389.00
Shares Outstanding (Mil.): 709.01
Dividend: 30.00
Yield (%): 3.45

Financials

  4568.T Industry Sector
P/E (TTM): 15.27 38.05 39.20
EPS (TTM): 114.04 -- --
ROI: 5.54 17.86 17.16
ROE: 8.40 18.61 18.09
Search Stocks

FDA panel backs Daiichi's blood thinner

- A panel of advisers to the U.S. Food and Drug Administration voted 9-1 in favor of approving Japanese drugmaker Daiichi Sankyo Co's blood thinner for use in some patients with atrial fibrillation.

30 Oct 2014

UPDATE 1-FDA panel backs Daiichi's blood thinner

* If approved, will compete with three new-generation drugs (Adds details, background)

30 Oct 2014

FDA panel backs Daiichi's blood thinner

Oct 30 - A panel of advisers to the U.S. Food and Drug Administration voted 9-1 in favor of approving Japanese drugmaker Daiichi Sankyo Co's blood clot and stroke preventer for use in some patients with atrial fibrillation.

30 Oct 2014

FDA staff recommends limited use of Daiichi's blood thinner

- U.S. Food and Drug Administration staff reviewers recommended approval of a 60 mg dose of Daiichi Sankyo Co's blood thinner for some atrial fibrillation patients, but suggested limiting its use to those with abnormal kidney function.

28 Oct 2014

UPDATE 1-FDA staff recommends limited use of Daiichi's blood thinner

Oct 28 - U.S. Food and Drug Administration staff reviewers recommended approval of a 60 mg dose of Daiichi Sankyo Co's blood thinner for some atrial fibrillation patients, but suggested limiting its use to those with abnormal kidney function.

28 Oct 2014

FDA staff recommends limited use of Daiichi's blood thinner

Oct 28 - U.S. Food and Drug Administration staff reviewers recommended approval of a 60 mg dose of Daiichi Sankyo Co's blood thinner for certain atrial fibrillation patients, but suggested limiting its use in those with abnormal kidney function.

28 Oct 2014

Japan's Daiichi Sankyo to acquire US biopharma Ambit Biosciences

TOKYO - Japanese drugmaker Daiichi Sankyo Co Ltd has agreed to acquire U.S. biopharmaceutical company Ambit Biosciences Corp in a deal valued up to $410 million as it looks to build its presence in oncology, the companies said.

29 Sep 2014

Japan's Daiichi Sankyo to acquire US biopharma Ambit Biosciences

TOKYO, Sept 29 - Japanese drugmaker Daiichi Sankyo Co Ltd has agreed to acquire U.S. biopharmaceutical company Ambit Biosciences Corp in a deal valued up to $410 million as it looks to build its presence in oncology, the companies said.

29 Sep 2014

INDIA PRESS-Sun Pharma banks on Daiichi Sankyo to crack Japan market-Economic Times

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aby Jose Koilparambil in Bangalore)

11 Aug 2014

Update-Moody's affirms Daiichi Sankyo's A1 rating; outlook stable

For the full text of this story please click the following link:

02 Jun 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
£10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks